Use of Nucala in Severe Asthma

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

2100 participants

Study Classification

OBSERVATIONAL

Study Start Date

2021-01-01

Study Completion Date

2022-05-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The Severe Heterogeneous Asthma Research collaboration, Patient-centred (SHARP) is set up to harmonise severe asthma management across Europe and unravel underlying heterogeneity in a patient-centred way. Using data from national registries included in the SHARP network, this study aims to evaluate real-world use of Nucala, describe characteristics of patients prescribed with Nucala and evaluate the effectiveness of Nucala in clinically relevant endpoints.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Real Life Experience Survey of Dupilumab in the Netherlands

NCT05331755

Severe Asthma

COMPLETED

GSK2190915 Moderate to Severe Asthma Study

NCT00850642

Asthma

TERMINATED PHASE2

REIMAGINE - Real World EvaluatIon of Mepolizumab in Severe Asthma achievinG on Treatment clinIcal remissioN, a prospEctive Study

NCT06041386

Asthma

ACTIVE_NOT_RECRUITING PHASE4

A Trial of Mepolizumab Adjunctive Therapy for the Prevention of Asthma Exacerbations in Urban Children

NCT03292588

Asthma

COMPLETED PHASE2

Effect of Mepolizumab on Severe Eosinophilic Asthma

NCT04641741

Asthma Eosinophilic Asthma

UNKNOWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The global prevalence of asthma is approximately 358 million people, of which an estimated 30 million patients live in Europe. Severe asthma is defined as asthma requiring treatment according to GINA steps 4-5 and is estimated to occur in 5-10% of the total asthma population (Chung 2014). Asthma and severe asthma are heterogeneous, and while there are a range of classifications, one such schema classified asthma as: (1) eosinophilic, (2) neutrophilic, (3) mixed, or (4) paucigranulocytic.

NUCALA (mepolizumab) is an IL-5 antagonist monoclonal antibody that was approved by the European commission in 2015 for add-on maintenance treatment of adult patients with severe refractory eosinophilic asthma. The license was expanded to paediatric patients (6-17 years old) in August 2018. Clinical efficacy was evaluated in multiple randomized, double-blind clinical trials. In the DREAM trial (NCT01000506), the rate of clinically significant exacerbations was 2.40 per patient per year among patients receiving placebo versus 1.24 in the 75 mg IV mepolizumab group, a 48% (95% CI 31-61%) reduction. In the MENSA trial (NCT01691521), the rate of clinically significant exacerbations was 1.74 per patient per year among patients receiving placebo versus 0.83 in the sub-cutaneous 100 mg mepolizumab group, a 53% (95% CI 36-65%) reduction. Furthermore, in the SIRIUS trial (NCT01691508), the median daily prednisone dose at weeks 20-24 was 10.0 mg among patients receiving placebo versus 3.1 mg for patients receiving 100 mg of mepolizumab and mepolizumab provided a 2.39 (95% CI 1.25-4.56) times greater odds for a reduction in oral glucocorticoid dose from baseline in the mepolizumab group compared with placebo. Additionally, the MUSCA trial (NCT02281318) found that mepolizumab significantly improved health-related quality of life in patients with severe eosinophilic asthma.

The high internal validity of the randomized clinical trials has allowed the treatment efficacy of Nucala to be reliably determined in patients with severe eosinophilic asthma. However, the strict inclusion and exclusion criteria which are necessary in clinical trials produce data from a selected, homogeneous population which may not be representative of the wider population who may receive treatments in routine practice.

Real world evaluation of mepolizumab use will help in understanding characteristics of patients from different European countries receiving these therapies, treatment patterns, and effectiveness on clinical endpoints as limited information exists in real world settings in Europe following the availability of mepolizumab to patients.

The Severe Heterogeneous Asthma Research collaboration, Patient-centred (SHARP) is set up to harmonise severe asthma management across Europe and unravel underlying heterogeneity in a patient-centred way. Using data from national registries included in the SHARP network, this study aims to evaluate real-world use of Nucala, describe characteristics of patients prescribed with Nucala and evaluate the effectiveness of Nucala in clinically relevant endpoints.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Asthma Severe Persistent Uncontrolled

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Patients treated with mepolizumab

Mepolizumab 100 MG

Intervention Type DRUG

Treatment with mepolizumab for severe asthma

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Mepolizumab 100 MG

Treatment with mepolizumab for severe asthma

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1\) Initiated on mepolizumab for treatment of asthma.

Exclusion Criteria

1\) Participation in an interventional clinical trial in which the treatment regimen and/or monitoring is dictated by a protocol in the study observation period.

Eligible Sex

ALL

Accepts Healthy Volunteers

No